Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 27 of 27 results for ustekinumab (psoriasis)

  1. Secukinumab for treating moderate to severe plaque psoriasis (TA350)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA350

  2. Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)

    Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    28 June 2023
    View recommendations

    Sections for TA907

  3. Apremilast for treating moderate to severe plaque psoriasis (TA419)

    Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA419

  4. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

    Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    24 May 2017
    View recommendations

    Sections for TA445

  5. Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.

    Technology appraisal guidance
    Published
    3 October 2018
    View recommendations

    Sections for TA543

  6. Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA768

  7. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)

    Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.

    Technology appraisal guidance
    Published
    10 August 2022
    View recommendations

    Sections for TA815

  8. Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

    Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    8 August 2018
    View recommendations

    Sections for TA537

  9. CT-P43 (ustekinumab biosimilar) for treating moderate to severe plaque psoriasis TS ID 11773

      Status ...

    Technology appraisal guidance
    Topic selection

  10. ABP-654 (ustekinumab biosimilar) for previously treated moderate to severe plaque psoriasis TS ID 11790

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Trials that evaluate utility values (using generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility analyses.

    generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility...

    Research recommendation
    Published
    15 October 2018

  12. Apremilast for treating active psoriatic arthritis (TA433)

    Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.

    Technology appraisal guidance
    Published
    22 February 2017
    View recommendations

    Sections for TA433